<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Current Report<BR>
Pursuant To Section&nbsp;13 or 15 (d)&nbsp;of the<BR>
Securities Exchange Act of 1934</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported) &#151; April&nbsp;30, 2008</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>NUCRYST PHARMACEUTICALS CORP.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in its charter)</B></DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B><FONT style="font-size:12pt">Alberta, Canada</FONT><BR>
(State or other jurisdiction of <BR>
incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B><FONT style="font-size:12pt">000-51686</FONT><BR>
(Commission File Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B><FONT style="font-size:12pt">Not Applicable</FONT><BR>
(I.R.S. Employer Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><B>NUCRYST Pharmaceuticals Corp.<BR>
50 Audubon Road<BR>
Wakefield, MA 01880</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Address of principal executive offices)</B></DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Registrant&#146;s telephone number, including area code: <FONT style="font-size:12pt">(780)&nbsp;992-5626</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><B>Not applicable</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Former name or former address, if changed since last report)</B></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (<I>see </I>General Instruction
A.2. below):
</DIV>
<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))</TD>
</TR>
</TABLE>
</DIV>

<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))</TD>
</TR>
</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">







<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B><I>Item&nbsp;5.02</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers</B></DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>(b)</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Departure of Certain Officer</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On April&nbsp;30, 2008, NUCRYST announced that Katherine J. Turner will be stepping down, effective
immediately as Vice President, Research and Development of the Company.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B><I>Item&nbsp;9.01</I></B>
</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Financial Statements and Exhibits.</B></DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>(d)</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Exhibits</I>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Press Release dated April&nbsp;30, 2008 titled &#147;NUCRYST Announces Management
Realignment and R&#038;D Portfolio Change&#148;.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><FONT style="font-variant: SMALL-CAPS"><B>Nucryst Pharmaceuticals Corp.</B></FONT><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left"><B>/s/ <I>Carol L. Amelio</I></B>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><B>Carol L. Amelio</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><B>Vice President, General Counsel and Corporate
Secretary</B>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">DATE:&nbsp;&nbsp;&nbsp;May&nbsp;6, 2008
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;99.1
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><IMG src="o40482o4048200.gif" alt="(NUCRYST LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NUCRYST Announces Management Realignment and R&#038;D Portfolio Change</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Wakefield, Massachusetts &#151; April&nbsp;30, 2008 &#151; </B>NUCRYST Pharmaceuticals, a developer and manufacturer
of medical products that fight infection and inflammation, today announced that the Company has
realigned its management team to further advance its cost reduction and growth strategies. The
realignment results in increased management responsibilities for David C. McDowell, Vice President
Operations and the appointment of Edward Gaj, Jr., RPh to the newly created position of Vice
President Marketing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company also announced that it has discontinued the development of, and out-licensing
initiatives for, the current formulation of NPI 32101 silver to treat inflammatory bowel disease
(IBD). Preclinical work will continue on the use of NPI 32101 silver for the treatment of
<I>Clostridium difficile</I>, as will the Company&#146;s other projects to develop line-extensions, product
improvements and new products for the treatment of infection and inflammation in hospitals,
specialty clinics and long-term care facilities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;I am confident that Dave and Ed&#146;s industry expertise, commitment to success and leadership skills
will contribute greatly to NUCRYST&#146;s future growth, and I am pleased to announce this significant
expansion of their responsibilities,&#148; said Thomas E. Gardner, Chairman and Chief Executive Officer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Effective May&nbsp;1, 2008, Mr.&nbsp;McDowell, a 24-year veteran of the pharmaceutical industry will add
Research and Development to his current responsibilities for Manufacturing, Quality/Regulatory and
Medical Affairs. Research and Development currently reports to Katherine J. Turner, PhD, Vice
President Research and Development, who has announced her intention to leave the Company to pursue
other opportunities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Mr.&nbsp;Gardner added, &#147;Following the Company&#146;s decision to consolidate management of Research and
Development activities in Canada, Katherine Turner advised us of her intention to explore
opportunities outside of NUCRYST. I want to thank Dr.&nbsp;Turner for her contributions during her
tenure at NUCRYST, and we wish her success in her future endeavors.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About </B><B><I>Clostridium difficile</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Clostridium difficile </I>(also called <I>C. difficile </I>or <I>C. diff</I>) is a bacterium that is recognized as
the major causative agent of colitis (inflammation of the colon) and diarrhea that may occur
following antibiotic intake. <I>C. difficile </I>infection represents one of the most widespread hospital
infections around the world. <I>C. difficile </I>may complicate the course of ulcerative colitis or
Crohn&#146;s disease and it is responsible for a significant occurrence of diarrhea in AIDS patients.
According to the Centers for Disease Control and Prevention, each year in the United States <I>C.
difficile </I>is responsible for tens of thousands of cases of diarrhea and at least 5,000 deaths.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About NUCRYST Pharmaceuticals</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical
products that fight infection and inflammation using its patented atomically disordered
nanocrystalline silver technology. Smith &#038; Nephew plc sell a range of advanced wound care products
under their Acticoat&#153; trade mark. Acticoat&#153; products incorporate NUCRYST&#146;s SILCRYST&#153; coatings and
are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address
medical conditions that are characterized by both infection and inflammation. The Company has
developed
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101 for use in
medical devices and as an active pharmaceutical ingredient.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For more information, contact:<BR>
Gregory W. Gin<BR>
Lazar Partners<BR>
212.867.1762<BR>
info@nucryst.com<BR>
Acticoat&#153; is a trademark of Smith &#038; Nephew plc<BR>
SILCRYST&#153; is a trademark of NUCRYST Pharmaceuticals Corp.

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>This news release contains forward-looking statements within the meaning of securities legislation
in the United States and Canada (collectively &#147;forward-looking statements&#148;). The words &#147;believes&#148;,
&#147;contribute&#148;, &#147;develop&#148;, &#147;advance&#148;, &#147;expects&#148;, &#147;plans&#148;, &#147;anticipates&#148;, &#147;estimates&#148;, &#147;intends&#148;,
&#147;projects&#148;, &#147;may&#148;, &#147;might&#148;, &#147;would&#148;, &#147;will&#148;, &#147;could&#148;, &#147;should&#148; and similar expressions are intended
to identify forward-looking statements, although not all forward-looking statements contain these
identifying words. Forward-looking statements in this news release include, but are not limited to,
statements about: our strategy, future operations, prospects and plans of management and our
ability to successfully develop new products, line extensions and product improvements, expand the
company&#146;s business and control costs. With respect to the forward-looking statements contained in
this news release, readers are cautioned that numerous risks, uncertainties and other factors could
cause our actual results to differ materially from those indicated in these statements including,
but not limited to: difficulties or delays in the initiation, timing, progress and results of our
preclinical trials and research and development programs relating to the development of products
containing our nanocrystalline silver for treatment of Clostridium difficile indications; our
ability to maintain our collaboration with Smith &#038; Nephew; our reliance on sales of Acticoat&#153;
products with our SILCRYST&#153; coatings by Smith &#038; Nephew; future sales of Acticoat&#153; may not be
sufficient to adequately fund our research and development plans; our future operation results are
uncertain and likely to fluctuate; we may not be able to retain existing and obtain new regulatory
approvals for our NPI 32101 barrier cream and any future products; our ability to successfully
achieve sustainable cost reductions; we may not be able to establish successful commercialization
programs, through new corporate collaborations or otherwise, for our NPI 32101 barrier cream or for
other future products; competition from other silver-based pharmaceutical or medical device
companies; our ability to raise additional financing required to fund further research and
development, clinical studies and obtain regulatory approvals, on commercially acceptable terms or
at all; changes in currency exchange rates; our ability to protect our intellectual property rights
and to not infringe on the intellectual property rights of others; our ability to comply with
governmental regulations and standards; our ability to successfully attract and retain skilled and
experienced personnel; changes in general economic and capital market conditions; other risks and
uncertainties unidentified at this time; and management&#146;s response to these factors. Although we
have attempted to identify the important risks, uncertainties and other factors that could cause
actual results or events to differ materially from those expressed or implied in forward-looking
statements, there may be other factors that cause actual results or events to differ from those
expressed or implied in forward looking statements. For a more thorough discussion of the risks
associated with our business, see the &#147;Risk Factors&#148; section in our Annual Report on Form 10-K for
the year ended December&nbsp;31, 2007, filed with the U.S. Securities and Exchange Commission on EDGAR
at <U>www.sec.gov</U> and with securities authorities in Canada on SEDAR at
<U>www.sedar.com</U>. All
forward-looking statements are expressly qualified in their entirety by this cautionary statement
and NUCRYST disclaims any intention or obligation to revise or update any forward-looking
statements whether as a result of new information, future developments or otherwise after the date
hereof.</I>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "o40482e8vk.htm", "description": "FORM 8-K", "secsgml_size_bytes": 19883}]
{"company-data": {"conformed-name": "NUCRYST Pharmaceuticals Corp.", "cik": "0001344674", "assigned-sic": "3841", "irs-number": "000000000", "state-of-incorporation": "A0", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51686", "film-number": "08808422"}, "business-address": {"street1": "50 AUDUBON ROAD", "street2": "SUITE B", "city": "WAKEFIELD", "state": "MA", "zip": "01880", "phone": "781-224-1444"}, "mail-address": {"street1": "50 AUDUBON ROAD", "street2": "SUITE B", "city": "WAKEFIELD", "state": "MA", "zip": "01880"}}
e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant To Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) — April 30, 2008
NUCRYST PHARMACEUTICALS CORP.
(Exact name of registrant as specified in its charter)
Alberta, Canada
(State or other jurisdiction of
incorporation or organization)
000-51686
(Commission File Number)
Not Applicable
(I.R.S. Employer Identification No.)
NUCRYST Pharmaceuticals Corp.
50 Audubon Road
Wakefield, MA 01880
(Address of principal executive offices)
Registrant's telephone number, including area code:
(780) 992-5626
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
(b)
Departure of Certain Officer
On April 30, 2008, NUCRYST announced that Katherine J. Turner will be stepping down, effective
immediately as Vice President, Research and Development of the Company.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
99.1
Press Release dated April 30, 2008 titled "NUCRYST Announces Management
Realignment and R&D Portfolio Change".
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Nucryst Pharmaceuticals Corp.
By:
/s/
Carol L. Amelio
Carol L. Amelio
Vice President, General Counsel and Corporate
Secretary
DATE:   May 6, 2008
Exhibit 99.1
NUCRYST Announces Management Realignment and R&D Portfolio Change
Wakefield, Massachusetts — April 30, 2008 —
NUCRYST Pharmaceuticals, a developer and manufacturer
of medical products that fight infection and inflammation, today announced that the Company has
realigned its management team to further advance its cost reduction and growth strategies. The
realignment results in increased management responsibilities for David C. McDowell, Vice President
Operations and the appointment of Edward Gaj, Jr., RPh to the newly created position of Vice
President Marketing.
The Company also announced that it has discontinued the development of, and out-licensing
initiatives for, the current formulation of NPI 32101 silver to treat inflammatory bowel disease
(IBD). Preclinical work will continue on the use of NPI 32101 silver for the treatment of
Clostridium difficile
, as will the Company's other projects to develop line-extensions, product
improvements and new products for the treatment of infection and inflammation in hospitals,
specialty clinics and long-term care facilities.
"I am confident that Dave and Ed's industry expertise, commitment to success and leadership skills
will contribute greatly to NUCRYST's future growth, and I am pleased to announce this significant
expansion of their responsibilities," said Thomas E. Gardner, Chairman and Chief Executive Officer.
Effective May 1, 2008, Mr. McDowell, a 24-year veteran of the pharmaceutical industry will add
Research and Development to his current responsibilities for Manufacturing, Quality/Regulatory and
Medical Affairs. Research and Development currently reports to Katherine J. Turner, PhD, Vice
President Research and Development, who has announced her intention to leave the Company to pursue
other opportunities.
Mr. Gardner added, "Following the Company's decision to consolidate management of Research and
Development activities in Canada, Katherine Turner advised us of her intention to explore
opportunities outside of NUCRYST. I want to thank Dr. Turner for her contributions during her
tenure at NUCRYST, and we wish her success in her future endeavors."
About
Clostridium difficile
Clostridium difficile
(also called
C. difficile
or
C. diff
) is a bacterium that is recognized as
the major causative agent of colitis (inflammation of the colon) and diarrhea that may occur
following antibiotic intake.
C. difficile
infection represents one of the most widespread hospital
infections around the world.
C. difficile
may complicate the course of ulcerative colitis or
Crohn's disease and it is responsible for a significant occurrence of diarrhea in AIDS patients.
According to the Centers for Disease Control and Prevention, each year in the United States
C.
difficile
is responsible for tens of thousands of cases of diarrhea and at least 5,000 deaths.
About NUCRYST Pharmaceuticals
NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical
products that fight infection and inflammation using its patented atomically disordered
nanocrystalline silver technology. Smith & Nephew plc sell a range of advanced wound care products
under their Acticoat™ trade mark. Acticoat™ products incorporate NUCRYST's SILCRYST™ coatings and
are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address
medical conditions that are characterized by both infection and inflammation. The Company has
developed
its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101 for use in
medical devices and as an active pharmaceutical ingredient.
For more information, contact:
Gregory W. Gin
Lazar Partners
212.867.1762
info@nucryst.com
Acticoat™ is a trademark of Smith & Nephew plc
SILCRYST™ is a trademark of NUCRYST Pharmaceuticals Corp.
This news release contains forward-looking statements within the meaning of securities legislation
in the United States and Canada (collectively "forward-looking statements"). The words "believes",
"contribute", "develop", "advance", "expects", "plans", "anticipates", "estimates", "intends",
"projects", "may", "might", "would", "will", "could", "should" and similar expressions are intended
to identify forward-looking statements, although not all forward-looking statements contain these
identifying words. Forward-looking statements in this news release include, but are not limited to,
statements about: our strategy, future operations, prospects and plans of management and our
ability to successfully develop new products, line extensions and product improvements, expand the
company's business and control costs. With respect to the forward-looking statements contained in
this news release, readers are cautioned that numerous risks, uncertainties and other factors could
cause our actual results to differ materially from those indicated in these statements including,
but not limited to: difficulties or delays in the initiation, timing, progress and results of our
preclinical trials and research and development programs relating to the development of products
containing our nanocrystalline silver for treatment of Clostridium difficile indications; our
ability to maintain our collaboration with Smith & Nephew; our reliance on sales of Acticoat™
products with our SILCRYST™ coatings by Smith & Nephew; future sales of Acticoat™ may not be
sufficient to adequately fund our research and development plans; our future operation results are
uncertain and likely to fluctuate; we may not be able to retain existing and obtain new regulatory
approvals for our NPI 32101 barrier cream and any future products; our ability to successfully
achieve sustainable cost reductions; we may not be able to establish successful commercialization
programs, through new corporate collaborations or otherwise, for our NPI 32101 barrier cream or for
other future products; competition from other silver-based pharmaceutical or medical device
companies; our ability to raise additional financing required to fund further research and
development, clinical studies and obtain regulatory approvals, on commercially acceptable terms or
at all; changes in currency exchange rates; our ability to protect our intellectual property rights
and to not infringe on the intellectual property rights of others; our ability to comply with
governmental regulations and standards; our ability to successfully attract and retain skilled and
experienced personnel; changes in general economic and capital market conditions; other risks and
uncertainties unidentified at this time; and management's response to these factors. Although we
have attempted to identify the important risks, uncertainties and other factors that could cause
actual results or events to differ materially from those expressed or implied in forward-looking
statements, there may be other factors that cause actual results or events to differ from those
expressed or implied in forward looking statements. For a more thorough discussion of the risks
associated with our business, see the "Risk Factors" section in our Annual Report on Form 10-K for
the year ended December 31, 2007, filed with the U.S. Securities and Exchange Commission on EDGAR
at
www.sec.gov
and with securities authorities in Canada on SEDAR at
www.sedar.com
. All
forward-looking statements are expressly qualified in their entirety by this cautionary statement
and NUCRYST disclaims any intention or obligation to revise or update any forward-looking
statements whether as a result of new information, future developments or otherwise after the date
hereof.